Phase IIa Efficacy and Safety Trial of capadenoson in Patients with Chronic Stable Angina

Update Il y a 4 ans
Reference: EUCTR2007-000425-22

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The main objective of this study is to demonstrate that chronic administration of BAY 68-4986 for 28 days at doses of 1 mg, 2 mg and 4 mg, is efficacious in a patient population with chronic stable angina and documented coronary heart disease. The primary efficacy parameter will be the total exercise time.


Inclusion criteria

  • Patients with Chronic Stable Angina

Links